瑞福生醫股份有限公司
Update：2026/11/10
Industries
Main Industry
Biotechnology
Main Product/Service
CYTOPACX BioMedicine Co., Ltd. mainly provides exosome-related technologies as well as products and services for regenerative medicine applications. These include neural stem cell exosomes, mesenchymal stem cell exosomes, and high-purity exosome preparation technologies, extending to the development of applications related to tissue repair and immunomodulation. Its technology platform can be applied to medical research and product development fields such as neural repair, anti-inflammatory regulation, and tissue regeneration. At the same time, it also extends to biotechnology application markets such as dietary supplements and skincare products, supporting the innovative development of clinical research and the healthcare industry.
The content above was translated by Ai
Founded Year
2022
Unified Business No.
90390280
Status
Active
Number of Employees
20
Total Paid-in
Capital
95,500,000 (NT$)
Location of Company
Taiwan
, Taipei City
Website
Company names, registration status, legal representatives, founding years, paid-in capital, registered addresses, and other details are sourced from business registration records maintained by Taiwan’s Administration of Commerce, Ministry of Economic Affairs. Exit status includes Emerging Stock Board listings, M&A, and IPOs. Information on overseas expansion is self-reported by startups.
Note 1: FINDIT compiles company information from public and other sources for reference and does not serve as a point of contact for the companies listed.
Note 2: Some company profiles and product/service descriptions are translated using AI and provided for reference only. In case of discrepancies or ambiguity, the original text prevails.
Exclusive content for members
Members-only content. Please log in to access.
About the Company
CYTOPACX BioMedicine Co., Ltd. was established by a founding team with backgrounds in medicine and biotechnology. Upholding the core philosophies of integrity in operations and continuous innovation, the company is committed to promoting the development of the biomedical industry and aligning with international standards. Based on a rigorous quality system and systematic operations, the company comprehensively strengthens consistency and traceability from manufacturing processes to management, ensuring the stability and reliability of overall operations. Meanwhile, CYTOPACX BioMedicine Co., Ltd. continues to integrate academic, clinical, and industrial resources, deepening cross-disciplinary cooperation and expanding international connections. With Taiwan as its starting point, the company is dedicated to building a biomedical platform with long-term competitiveness, driving the continuous evolution of the industry, and creating robust value for global health and future development.
The content above was translated by Ai
